Investigational drug · Phase 3
DA-001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Telogen Effluvium, Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "DA-001"
First trial start
2026
May 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DA-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Telogen Effluvium
- Female Pattern Hair Loss
- Female Pattern Hair Loss, Androgenic Alopecia
- Male Pattern Baldness
- Androgenetic Alopecia
- Androgenetic Alopecia (AGA)
Approved drugs for the same conditions: Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "DA-001" as an intervention, largest first.
- Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-GrowthPivotal-lookingNot yet recruiting
Applied Biology, Inc.Industry
NCT06648850 · 1,120 participants (planned) · Start May 1, 2026 · Primary completion Mar 19, 2027
Drug: DA-001; Phenylephrine and 1 more · For: Telogen Effluvium; Female Pattern Hair Loss; Female Pattern Hair Loss, Androgenic Alopecia and 3 more
- An Exploratory Clinical Study of UX-DA001 in Subjects With Idiopathic Parkinson's DiseaseActive, not recruiting
Shanghai UniXell Biotechnology Co., LtdIndustry
NCT06778265 · 12 participants (planned) · Start Mar 1, 2025 · Primary completion Dec 2027
Drug: UX-DA001 · For: Parkinson Disease, Idiopathic
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.